DENVER, Colo. (247marketnews.com) — Altimmune (NASDAQ:ALT) delivered one of its most significant clinical milestones to date, reporting positive topline results from its RECLAIM Phase 2 trial evaluating pemvidutide in patients with moderate to severe alcohol use disorder (AUD). The investigational dual glucagon/GLP-1 receptor agonist met the study’s primary endpoint, producing a statistically significant reduction in heavy drinking days compared with placebo while also achieving multiple important secondary endpoints recognized by the U.S. Food and Drug Administration (FDA) as potential registrational measures.
The trial demonstrated meaningful improvements across several key measures of alcohol consumption. Patients receiving pemvidutide experienced significantly fewer heavy drinking days, while nearly two-thirds achieved a two-level reduction in the World Health Organization’s Risk Drinking Levels, a clinically meaningful outcome that is recognized by the FDA as a registrational endpoint. The study also showed a significantly greater proportion of patients achieving zero heavy drinking days, increased abstinence, and a sharp reduction in phosphatidylethanol (PEth), an objective biomarker used to measure alcohol intake. In addition, participants receiving pemvidutide experienced a placebo-adjusted 9.1% reduction in body weight over 24 weeks, with no evidence that weight loss had plateaued by the end of the study.
Safety remains an important consideration for any therapy targeting metabolic disease, and Altimmune reported that pemvidutide demonstrated a generally favorable tolerability profile. As seen with other GLP-1-based therapies, the most common adverse events were gastrointestinal, including nausea, vomiting, diarrhea, and constipation, with most events characterized as mild to moderate in severity. Treatment discontinuation rates were comparable between the pemvidutide and placebo groups, although a small number of discontinuations in the treatment arm were attributed to drug-related adverse events.
The results may have implications well beyond alcohol use disorder. Pemvidutide is being developed as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH), alcohol-associated liver disease (ALD), and AUD, creating the possibility of a single therapy addressing multiple diseases that frequently occur together. Unlike traditional GLP-1 therapies, pemvidutide combines balanced glucagon and GLP-1 receptor activity, a mechanism designed not only to promote weight loss but also to directly target liver fat, inflammation, and fibrosis. The program has already received FDA Fast Track designation for both MASH and AUD, as well as Breakthrough Therapy designation for MASH.
The broader market opportunity remains substantial. According to the company, approximately 28 million adults in the United States are estimated to have alcohol use disorder, yet fewer than 2% receive one of the three currently approved FDA therapies, reflecting the limited effectiveness of existing treatment options and the significant unmet medical need. As interest grows in GLP-1-based medicines beyond obesity and diabetes, positive data in addiction and liver disease could further expand the therapeutic potential of this drug class.
Altimmune plans to request an End-of-Phase 2 meeting with the FDA to discuss the regulatory path forward for pemvidutide in AUD. Meanwhile, enrollment in the company’s RESTORE Phase 2 trial in alcohol-associated liver disease is expected to conclude during the third quarter of 2026, and the PERFORMA Phase 3 trial in MASH is scheduled to begin later this year. Together, these milestones position pemvidutide as a potentially differentiated late-stage asset spanning multiple large disease markets. While additional clinical testing and regulatory review remain ahead, the RECLAIM results represent a meaningful step forward in establishing the drug’s broader therapeutic profile.
Sources
-
Altimmune Corporate Website: https://www.altimmune.com
-
U.S. Food and Drug Administration – Fast Track Development Program: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track
-
World Health Organization – Alcohol Facts: https://www.who.int/news-room/fact-sheets/detail/alcohol
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.